Scots fund Novartis' Glivec but not Roche's RoActemra or GSK's Benlysta
This article was originally published in Scrip
Executive Summary
The Scottish Medicines Consortium, Scotland's health technology appraisal body, has agreed to make available on the local NHS Novartis' Glivec (imatinib) for some gastrointestinal stromal tumour (GIST) patients for a longer duration of treatment. However, neither Roche nor GSK were able to convince the consortium to recommend their drugs, RoActemra (tocilizumab, as monotherapy) and Benlysta (belimumab) respectively.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.